FDA Class I Recall

More anesthesia machines added to correction for potential ventilation failure

The U.S. Food and Drug Administration (FDA) has designated a recent expansion of Draeger, Inc.’s Atlan anesthesia workstation correction as a Class I recall, the agency’s most serious recall classification.

What makes this action particularly noteworthy is that it expands a correction originally announced in October 2024, raising questions about the scope and duration of the underlying manufacturing issue.

The correction affects certain Draeger Atlan A350 and Atlan A350 XL anesthesia workstations used to deliver inhaled anesthesia and mechanical ventilation during surgical and diagnostic procedures involving adults, children, and neonates.

According to Draeger, a manufacturing defect involving the ventilator motor assembly may cause the piston ventilator to fail either before use or during active patient ventilation. If the failure occurs before a procedure, mechanical ventilation cannot be initiated. If it occurs during a procedure, the workstation displays a “Ventilator error!!!” alarm and automatic ventilation ceases.

Manual ventilation remains available and monitoring functions continue to operate.

Why This Matters

Mechanical ventilation is a critical life-support function during anesthesia. According to FDA, failure of the ventilation system could potentially result in hypoxia (oxygen deprivation), loss of lung recruitment, Bradycardia, cardiac arrest, or death.

Although no injuries or deaths have been reported, FDA classified both the original correction and the recent expansion as Class I actions because of the severity of potential patient harm.

What’s New?

The May 2026 action expands Draeger’s October 2024 correction to include additional Atlan A350 and A350 XL workstations. The company states that additional devices require replacement of the ventilator motor assembly due to the same manufacturing-related issue identified during the original correction.

Affected facilities may continue using the devices under constant supervision until Draeger completes replacement of the ventilator motor assembly. If ventilation failure occurs, clinicians are instructed to immediately switch to Manual/Spontaneous ventilation mode and manually ventilate the patient.

Regulatory Perspective

The expansion of a Class I field correction nearly two years after the original action is unusual and raises several important quality-system questions.

Was the affected population initially underestimated?

Were additional devices identified through complaint trending or service records?

Did subsequent investigations uncover a broader manufacturing impact?

How effective was the original correction strategy in identifying all affected units?

At present, neither FDA nor Draeger has reported injuries, deaths, or patient harm associated with the issue. That is significant.

In many Class I recalls involving life-support equipment, patient harm is often what drives regulatory escalation. In this case, the combination of alarm functionality, continued monitoring capability, and the availability of manual ventilation appears to have provided effective risk controls while corrective actions are implemented.

What Healthcare Facilities Should Do

Facilities using affected Atlan A350 and Atlan A350 XL anesthesia workstations should coordinate with Draeger representatives to schedule replacement of affected ventilator motor assemblies.

In addition, facilities can continue operating devices under close supervision, ensure clinical staff are aware of the correction, and be prepared to transition immediately to Manual/Spontaneous ventilation mode if a ventilator error occurs.

MDP Regulatory Perspective

This recall serves as a reminder that postmarket corrective actions do not always end with the initial field notification. Even well-executed investigations may continue to evolve as manufacturers analyze service records, complaint data, production history, and field performance trends.

For regulatory and quality professionals, one of the most important questions is not simply why the correction was expanded, but how the manufacturer identified the need for expansion and whether the processes used to identify affected devices were sufficiently robust during the original 2024 action.

As FDA and manufacturers continue to emphasize risk-based postmarket surveillance, this case demonstrates how corrective actions can remain active and evolve years after the initial field action is launched.

Links

Read the FDA’s announcement here.